5 Tips for Traveling with a Chronic Disease from a Patient with Psoriatic Arthritis
(BPT) - Sponsored by Lilly USA, LLC
Source: nny360.com
📰 Medication Guide News
Page 31 - Medication Guide News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Medication Guide. Real-time updates on events, politics, business and more.
Danco Moves to Intervene in Lawsuit Challenging FDA Approval of Mifeprex®
/PRNewswire/ -- Today, Danco Laboratories (Danco) filed a motion to intervene in Alliance for Hippocratic Medicine v. FDA, a lawsuit in which several...
United States Amarillo Division Alliance For Hippocratic Medicine Us District Court Danco Laboratories Hippocratic Medicine
Source: prnewswire.com
Novo Nordisk announces FDA approval of label update for Rybelsus® (semaglutide) allowing use as a first-line option for adults with type 2 diabetes
/PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved a label update for Rybelsus® (semaglutide) tablets 7 mg or 14 mg, allowing use as a...
Source: prnewswire.com
XELSTRYM™ (dextroamphetamine) transdermal system, CII, to be revealed as available soon at the 2023 American Professional Society of ADHD and Related Disorders (APSARD) Conference
/PRNewswire/ -- Noven Pharmaceuticals. Inc., (Noven), a wholly owned subsidiary of Hisamitsu Pharmaceutical Co., Inc. focusing on the development of...
United States Naruhito Higo Greg Mattingly Natalie Andrade Noven Pharmaceuticals Hisamitsu Pharmaceutical Co Inc
Source: prnewswire.com
A TV Journalist Shares Her Experience Trying Injectables for the First Time
Amanda Balionis Renner shares her experience using Xeomin (incobotulinumtoxinA) to smooth the appearance of frown lines.
Amanda Balionis Renner Merz North America Inc Medication Guide Important Safety Information Full Prescribing Information North America
Source: cosmopolitan.com
Moderna, Inc.: Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA , Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial
MRNA-4157/V940, in combination with KEYTRUDA, demonstrated a statistically significant and clinically meaningful reduction in the risk of disease recurrence or death compared to KEYTRUDA monotherapy in
Source: finanznachrichten.de
Investegate |Moderna Inc Announcements | Moderna Inc: Moderna and Merck Announce mRNA Cancer Vaccine
Investegate announcements from Moderna Inc, Moderna and Merck Announce mRNA Cancer Vaccine
Source: investegate.co.uk
MorphoSys Presents Updated Tafasitamab Results in Newly Diagnosed DLBCL Patients from Final firstMIN
EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys Presents Updated Tafasitamab Results in Newly Diagnosed DLBCL Patients from Final firstMIND Analysis at ASH 2022 10.12.2022 / 23:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media Release  PLANEGG/MUNICH, Germa...
Source: pharmiweb.com
AbbVie to Showcase Migraine Portfolio and Pipeline During the 16th European Headache Federation Congress
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that data from its robust migraine portfolio will be presented at the 16th European Headache Federation...
United Kingdom Lou Gehrig Mudra Kapoor European Headache Federation Congress European Medicines Agency United Kingdom Or European Union
Source: prnewswire.com
Idorsia Pharmaceuticals Ltd: Swissmedic approves QUVIVIQ (daridorexant) - a first-in-class treatment for chronic insomnia disorder to improve both nighttime symptoms and daytime functioning
QUVIVIQ is indicated for the treatment of adult patients with insomnia characterized by symptoms present for at least three months and considerable impact on daytime functioningQUVIVIQ, Switzerland's first
Source: finanznachrichten.de